Growth hormone treatment in a girl with Prader Willi syndrome.

Abstract

Prader Willi syndrome (PWS) is a rare endocrine-metabolic disorder that is characterised by neonatal hypotonia, hyperphagia, marked obesity, short stature, hypogonadism and behavioural problems. 7-20% percent of these children develop diabetes mellitus. A large number of individuals with PWS show growth hormone (GH) deficiency. Recent studies indicate beneficial effects of GH replacement therapy not only for their linear growth but also for correction of metabolic dysfunction. In the present communication this article details about the therapeutic outcome in a girl with PWS who received recombinant growth hormone (rGH), Genotropin. Some carry-over therapeutic benefits have been observed even after discontinuation of rGH.

• Authors: S N Pandey, R A Vaidya, A Irani
• Journal: Indian journal of pediatrics (Indian J Pediatr) Vol. 70 Issue 4 Pg. 351-3 (Apr 2003) ISSN: 0019-5456 [Print] India
• PMID: 12793314 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Pituitary Hormones, Anterior
• Recombinant Proteins
• Human Growth Hormone

Topics

• Adolescent
• Female
• Glucose Tolerance Test
• Growth (drug effects)
• Human Growth Hormone (blood, therapeutic use)
• Humans
• Pituitary Hormones, Anterior (blood)
• Prader-Willi Syndrome (blood, diagnosis, drug therapy)
• Recombinant Proteins (therapeutic use)
• Treatment Outcome